Announcements
- Immutep Announces Positive Preliminary Topline Results from TACTI-003 Cohort B
- Immutep Reports Promising Clinical Data from INSIGHT-003 Trial at ESMO Congress 2023
- Immutep’s Efti in Combination with KEYTRUDA® Generates Excellent Overall Survival Benefit in Patients with Metastatic Non-Small Cell Lung Cancer
- Immutep’s Efti in Combination with Pembrolizumab Achieves Excellent Initial Overall Survival Benefit in 1st Line Non-Small Cell Lung Cancer
Key statistics
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 2.48 |
---|---|
High | 2.48 |
Low | 2.46 |
Bid | 2.46 |
Offer | 2.54 |
Previous close | 2.64 |
Average volume | 468.00 |
---|---|
Shares outstanding | -- |
Free float | -- |
P/E (TTM) | -- |
Market cap | -- |
EPS (TTM) | -- |
Data delayed at least 15 minutes, as of Apr 30 2024.
More ▼